[go: up one dir, main page]

MX2009007001A - Aminoacidos y polipeptidos fenazina y quinoxalina sustituidos. - Google Patents

Aminoacidos y polipeptidos fenazina y quinoxalina sustituidos.

Info

Publication number
MX2009007001A
MX2009007001A MX2009007001A MX2009007001A MX2009007001A MX 2009007001 A MX2009007001 A MX 2009007001A MX 2009007001 A MX2009007001 A MX 2009007001A MX 2009007001 A MX2009007001 A MX 2009007001A MX 2009007001 A MX2009007001 A MX 2009007001A
Authority
MX
Mexico
Prior art keywords
polypeptides
amino acids
phenazine
natural amino
substituted amino
Prior art date
Application number
MX2009007001A
Other languages
English (en)
Inventor
Zhenwei Miao
Original Assignee
Ambrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrx Inc filed Critical Ambrx Inc
Publication of MX2009007001A publication Critical patent/MX2009007001A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C07K14/615—Extraction from natural sources

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se revelan en la presente aminoácidos no naturales y polipéptidos que incluyen por lo menos un aminoácido no natural y métodos para la fabricación de tales aminoácidos no naturales y polipéptidos. Los aminoácidos no naturales, por si mismos o como parte de un polipéptido, pueden incluir un sustituyente de fenazina o quinoxalina. También se revelan en la presente polipéptidos de aminoácidos no naturales que son modificados además post-traduccionalmente, métodos para efectuar tales modificaciones y métodos para la purificación de tales polipéptidos.
MX2009007001A 2006-12-28 2007-12-28 Aminoacidos y polipeptidos fenazina y quinoxalina sustituidos. MX2009007001A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88250006P 2006-12-28 2006-12-28
PCT/US2007/089142 WO2008083346A1 (en) 2006-12-28 2007-12-28 Phenazine and quinoxaline substituted amino acids and polypeptides

Publications (1)

Publication Number Publication Date
MX2009007001A true MX2009007001A (es) 2009-07-10

Family

ID=39589004

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007001A MX2009007001A (es) 2006-12-28 2007-12-28 Aminoacidos y polipeptidos fenazina y quinoxalina sustituidos.

Country Status (8)

Country Link
US (1) US20100098630A1 (es)
EP (1) EP2076500A4 (es)
JP (1) JP2010514808A (es)
KR (1) KR20090102838A (es)
AU (1) AU2007341997A1 (es)
CA (1) CA2671851A1 (es)
MX (1) MX2009007001A (es)
WO (1) WO2008083346A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2068909B1 (en) 2007-03-30 2012-04-25 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
CA2739445A1 (en) * 2008-10-03 2010-04-08 Advanced Proteome Therapeutics, Inc. Site specific n-terminal modifications of proteins and conjugate formation
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
SI2605789T1 (sl) 2010-08-17 2019-10-30 Ambrx Inc Modificirani polipeptidi relaksina in njihova uporaba
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
EA032056B1 (ru) 2010-12-22 2019-04-30 Баксалта Инкорпорейтид Конъюгат терапевтического белка и производного жирной кислоты, способы получения конъюгата терапевтического белка и производного жирной кислоты (варианты)
KR20140016262A (ko) 2011-01-14 2014-02-07 레드우드 바이오사이언스 인코포레이티드 알데하이드-태깅된 면역글로불린 폴리펩타이드 및 이의 사용 방법
US20150018530A1 (en) * 2012-02-29 2015-01-15 Ambrx, Inc. Novel Prodrug Containing Molecule Compositions and Their Uses
RS61664B1 (sr) 2012-04-24 2021-04-29 Vertex Pharma Inhibitori dna-pk
DK2859017T3 (da) 2012-06-08 2019-05-13 Sutro Biopharma Inc Antistoffer omfattrende stedsspecifikke ikke-naturlige aminosyrerester, fremgangsmåder til fremstilling heraf og fremgangsmåder til anvendelse heraf
ES2611788T3 (es) 2012-06-26 2017-05-10 Sutro Biopharma, Inc. Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
CN104981254B (zh) 2012-08-31 2018-05-22 苏特罗生物制药公司 含有叠氮基的经修饰的氨基酸
HUE057527T2 (hu) 2013-03-12 2022-05-28 Vertex Pharma DNS-PK inhibitorok
WO2014153002A1 (en) 2013-03-14 2014-09-25 The California Institute For Biomedical Research Bispecific antibodies and uses thereof
ES2865473T3 (es) 2013-07-10 2021-10-15 Sutro Biopharma Inc Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
AU2014337367B2 (en) 2013-10-15 2020-04-30 The Scripps Research Institute Peptidic chimeric antigen receptor T cell switches and uses thereof
HRP20181841T1 (hr) 2013-10-17 2019-01-11 Vertex Pharmaceuticals Incorporated Sukristali (s)-n-metil-8-(1-((2′-metil-[4,5′-bipirimidin]-6-il)amino)propan-2-il)kinolin-4-karboksamida i njegovih deuteriranih derivata kao inhibitora dna-pk
LT3412302T (lt) 2014-10-24 2021-07-26 Bristol-Myers Squibb Company Modifikuoti fgf-21 polipeptidai ir jų panaudojimai
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
CN114796520A (zh) 2016-01-27 2022-07-29 苏特罗生物制药公司 抗cd74抗体偶联物，包含抗cd74抗体偶联物的组合物以及抗cd74抗体偶联物的使用方法
CN109069635B (zh) 2016-02-04 2023-09-26 斯克利普斯研究所 人源化抗cd3抗体、偶联物及其用途
EP3448885A4 (en) 2016-04-26 2020-01-08 R.P. Scherer Technologies, LLC ANTIBODY CONJUGATES AND METHOD FOR THE PRODUCTION AND USE THEREOF
JP2019529475A (ja) 2016-09-27 2019-10-17 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ損傷剤とｄｎａ−ｐｋ阻害剤との組合せ物を使用する、がんを処置するための方法
AU2017345479B2 (en) 2016-10-19 2024-03-21 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
WO2019241430A2 (en) 2018-06-12 2019-12-19 Angiex, Inc. Antibody-oligonucleotide conjugates
HUE065882T2 (hu) 2018-09-11 2024-06-28 Ambrx Inc Interleukin-2-polipeptid-konjugátumok és alkalmazásaik
CA3131391A1 (en) 2019-02-27 2020-09-03 Angiex, Inc. Antibody-drug conjugates comprising anti-tm4sf1 antibodies and methods of using the same
US20230095053A1 (en) 2020-03-03 2023-03-30 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
CN113368111B (zh) * 2020-03-10 2022-04-22 四川大学 一种吩嗪羧酸类化合物的抗肿瘤作用
CN111440087A (zh) * 2020-04-08 2020-07-24 南京优氟医药科技有限公司 氧-[2-[2-[2-(2-甲氧基乙氧基)乙氧基]乙氧基]乙基]羟胺的生产工艺
CN113008853B (zh) * 2021-02-25 2023-01-24 中国工程物理研究院化工材料研究所 基于荧光含能分子对炸药的原位标记与视觉示踪的方法
EP4598586A1 (en) 2022-10-07 2025-08-13 Ambrx, Inc. Drug linkers and antibody conjugates thereof
CN120882432A (zh) 2023-01-16 2025-10-31 Ambrx 公司 抗cd70抗体-药物缀合物
WO2024178310A1 (en) 2023-02-23 2024-08-29 Ambrx, Inc. Trop2-directed antibody-drug conjugates and uses thereof
AR131133A1 (es) 2023-05-24 2025-02-19 Ambrx Inc INTERFERÓN l BOVINO PEGILADO Y MÉTODOS DE USO DEL MISMO
WO2025041055A1 (en) 2023-08-22 2025-02-27 Ambrx, Inc. Anti-psma adc conjugate compositions and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4170654A (en) * 1976-02-13 1979-10-09 Merck & Co., Inc. Antihypertensive compositions containing N-heterocyclicalanines and α-
US5118675A (en) * 1991-02-15 1992-06-02 American Home Products Corporation Quinoxaline phosphono-amino acids
DE10332560B4 (de) * 2003-07-11 2010-07-08 Chiracon Gmbh Verfahren zur Herstellung von ß- Heteroaryl-2-alanin-Verbindungen über 2-Amino-2-(heteroarylmethyl)-carbonsäure-Verbindungen

Also Published As

Publication number Publication date
EP2076500A1 (en) 2009-07-08
US20100098630A1 (en) 2010-04-22
AU2007341997A1 (en) 2008-07-10
KR20090102838A (ko) 2009-09-30
CA2671851A1 (en) 2008-07-10
WO2008083346A1 (en) 2008-07-10
JP2010514808A (ja) 2010-05-06
EP2076500A4 (en) 2009-12-09

Similar Documents

Publication Publication Date Title
MX2009007001A (es) Aminoacidos y polipeptidos fenazina y quinoxalina sustituidos.
SG170116A1 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
MX2009006617A (es) Composiciones que contienen, metodos que involucran y usos de aminoacidos y polipeptidos no naturales.
WO2007079130A3 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
GB2438982A (en) Compostions containing, methods involving, and uses of non-natural amino acids and polypeptides
EA201170878A1 (ru) Полипептиды с ксиланазной активностью
WO2011036443A9 (en) S1 protease c- terminal polypeptides and uses thereof for treating inflammation or coagulation disorders
IN2014CN02050A (es)
EA201001881A1 (ru) Пролинспецифичная протеаза из penicillium chrysogenum
CA2691692C (en) Prevention of disulfide bond reduction during recombinant production of polypeptides
NZ596658A (en) Dig-10 insecticidal cry toxins
NZ600690A (en) Fkbp-l and uses thereof
GB2431658A (en) Biosynthetic polypeptides utilizing non-naturally encoded amino acids
JOP20190083A1 (ar) بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
WO2006127757A3 (en) Interferon-igg fusion
IN2012DN03368A (es)
WO2011063320A3 (en) Recombinant filaggrin polypeptides for cell importation
EP2039367A4 (en) PROPHYLACTIC / THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASE
WO2007075438A3 (en) Polypeptides comprising unnatural amino acids, methods for their production and uses therefor
WO2007036299A3 (de) Verfahren zur amidierung von polypeptiden mit c-terminalen basischen aminosäuren unter verwendung spezifischer endoproteasen
WO2011056954A3 (en) Haemophilus parasuis polypeptides and methods of use
WO2005059131A3 (en) Protein binding miniature proteins and uses thereof
WO2007085728A3 (fr) Composition comprenant plusieurs toxines botuliques
NZ601647A (en) Variant hhip1 protein and methods and uses thereof
WO2006132739A3 (en) Novel chemical compounds

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal